Fish and Aquatic Conservation

Hydrogen peroxide (35% Perox Aid®) INAD #11-669

photo of a Lahontan Cutthroat Trout spawning in Glen Alpine Creek
Lahontan Cutthroat Trout spawning in Glen Alpine Creek. Credit: M. Conte/USFWS


35% Perox-Aid® (H2O2) is a liquid solution containing hydrogen peroxide that is applied as an immersion bath treatment. H2O2 is only available for purchase through Syndel USA. The primary goal of field studies conducted under INAD #11-669 is to evaluate the efficacy of H2O2 for controlling mortality caused by specific ectoparasites in freshwater or marine finfish species. It is also expected that the additional data will be used to expand the current H2O2 label claim. INAD use is for non-labeled use only and all labeled use must follow the approved label. Multiple treatment regimens are available for H2O2 so the study protocol needs to be reviewed before any treatments are administered. The Investigational withdrawal period for H2O2 is zero days for treated fish under any of the allowed treatment regimens. To participate in the INAD Program for H2O2 visit the data collecting site.

Please read the Study Protocol prior to any treatments. It contains the protocol, MSDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson.

INAD objective/purpose: Collect supportive and/or pivotal data needed to establish the effectiveness and safety of 35% PEROX-AID® to control mortality caused by extoparasites in a variety of fish species.

Drug Name
35% PEROX-AID® (hydrogen peroxide)

Drug Source
Syndel USA
1441 W Smith Rd,
Ferndale, WA 98248 USA

Jason Montgomery
Phone: 800-283-5292
Fax: 360-384-0270

Target pathogen(s): Ectoparasites of the genera Ambiphrya, Chilodonella, Dactylogyrus, Epistylis, Gyrodactylus, Ichthyobodo, Ichthyophthirius, Trichodina, Trichophrya, Argulus, Salmincola, Lernaea, and Ergasilus in freshwater fish species; and of the genera Neobenedenia, Amyloodinium, Cryptocaryon, and Uronema in marine fish species.

Method of administration: Immersion bath

Treatment dosage:

  • Option A: 100 or 150 mg/L;
  • Option B: 50, 75 or 100 mg/L;
  • Option C: 200 mg/L;
  • Option D: 400 mg/L - saltwater sea cages

Treatment regimen:

  • Option A: Treatment duration is 30 min; 3 consecutive or alternate days
  • Option B: Treatment duration is 60 min; 3 consecutive or alternate days
  • Option C: Treatment duration is 30 min; 3 consecutive or alternate days
  • Option D: 45 min; once per week for saltwater fish in open-water sea cages

Investigational Withdrawal period:

  • None. Fish may be allowed to enter the food chain immediately after treatment.

Required test parameters:

  • Investigator must collect mortality data throughout the 5 day pre-treatment, treatment, and 10 day post-treatment periods. Investigator should also report general fish behavior and any possible adverse effects relating to treatment.

Limitations or restrictions on use of drug:

  • Investigator must follow all instructions in the Study Protocol for INAD 11-669 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements.
  • Drug discharge must be in compliance with local NPDES permitting requirements.

Required INAD fee: $700/facility/year

AADAP Contact Information:
Ms. Bonnie Johnson, FWS-AADAP
Phone: 406-994-9905
Fax: 406-582-0242